Абстракт

Objectives: To introduce a new era of metabolic medicine and its intersection with aesthetics, addressing the widespread effects of GLP-1 receptor agonists on the skin, facial aging, body composition and discuss strategies to prevent and address "ozempic face". To highlight next generation GLP-1 RA medications and introduce the wide range of other bioregulatory peptides used to improve health, metabolism, performance, appearance and aging including; BPC-157, Epithalon, GHK-Cu, and more. To provide strategies to incorporate metabolic medicine, GLP-1 RAs and peptides into a regenerative aesthetics. Introduction: A new era of medicine has arrived with the technology and treatments to enable metabolic reprogramming. From drug assisted weight loss to targeted fat loss procedures, to peptide therapy, we have more options than ever before to help patients achieve their body’s best from the inside out. With widespread adoption of GLP1-RA medications, a new aesthetic phenomena has arisen: Ozempic face. A regenerative aesthetic, proactive and personalized approach to the skin, face and body can mitigate unwanted effects of rapid weight loss and enable metabolic reprogramming. Materials / method: Evidence was reviewed on facial volume loss associated with GLP-1 RA use and the associated effects of rapid weight loss on deep and superficial fat pads and on the loss of dermal white adipose tissue (DWAT) which in turn produces estrogen in the skin. Aesthetic strategies were evaluated included regenerative biostimulators, collagen-inducing injectables, peptide therapies, and wholistic personalized cosmetic plans. Preventive protocols were analyzed for efficacy. Use of micro-dosing (sub-therapeutic doses), additional peptides (BPC-157, GHK-Cu) powerful senolytics and anti-oxidants. Results: Patients managed with proactive metabolic–aesthetic protocols achieved improved outcomes. Early use of regenerative therapies preserved fibroblast activity and ECM integrity, mitigating skin sagging and hollowing. Integrated treatment synchronized with weight loss stabilized contours and enhanced both facial appearance and overall satisfaction. Patients who were must successful concomitantly incorporated hormone therapy, peptides, and aesthetic procedures. Conclusion: The widespread adoption of GLP-1 RAs are transforming health care and aesthetic practice. The metabolic benefits extend far beyond the first two indications (Diabetes and Anosmia). Next generation GLP-1 RAs are on the way with a large portfolio of bioregulatory peptides, hormones and senolytics finding a new place in aesthetic medicine. Proactive, bespoke metabolic–aesthetic care—including regenerative therapies and biostimulators—prevents “Ozempic Face” and elevates patient outcomes. A paradigm shift toward synchronized metabolic and aesthetic medicine is key to truly holistic patient care.